CVRx, Inc. (CVRX): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
CVRX Stock Price Chart Interactive Chart >
CVRX Price/Volume Stats
|Current price||$15.77||52-week high||$29.00|
|Prev. close||$14.65||52-week low||$14.00|
|Day high||$15.84||Avg. volume||166,493|
|50-day MA||$19.31||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||320.86M|
CVRx, Inc. (CVRX) Company Bio
CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.
Most Popular Stories View All
CVRX Latest News Stream
|Loading, please wait...|
CVRX Latest Social Stream
View Full CVRX Social Stream
Latest CVRX News From Around the Web
Below are the latest news stories about CVRx Inc that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced it will be added as a member of the Russell 2000® and 3000® Indexes, effective after the U.S. market opens on September 20, as part of the Russell’s quarterly additions of select initial public offe
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH...
Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year
MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Canaccord Genuity 41 st Annual Growth Conference on Thursday, August 12, 2021. The Company is scheduled to present at the conference at 11:00 am Eastern Time the same day via webcast.
Verde Investments made a bid to acquire land-management REIT Landmark Infrastructure. New Enterprise Associates disclosed a large stake in medical-device maker CVRx.
CVRX Price Returns